Intestinal microbiota in the treatment of metabolically associated fatty liver disease

World J Clin Cases. 2022 Nov 6;10(31):11240-11251. doi: 10.12998/wjcc.v10.i31.11240.

Abstract

Metabolically associated fatty liver disease (MAFLD) is a common cause of chronic liver disease, the hepatic manifestation of metabolic syndrome. Despite the increasing incidence of MAFLD, no effective treatment is available. Recent research indicates a link between the intestinal microbiota and liver diseases such as MAFLD. The composition and characteristics of the intestinal microbiota and therapeutic perspectives of MAFLD are reviewed in the current study. An imbalance in the intestinal microbiota increases intestinal permeability and exposure of the liver to adipokines. Furthermore, we focused on reviewing the latest "gut-liver axis" targeted therapy.

Keywords: Adipokines; Gut-liver axis; Intestinal microbiota; Metabolically associated fatty liver disease; Therapy.

Publication types

  • Review